Rep. Matt Rosendale Introduces Legislation: DSH 340B Eligibility Moratorium, Regulations Limiting Such Eligibility, and Increased Reporting Requirements
On September 30, U.S. Representative Matt Rosendale (R-MT) introduced the Drug Pricing Transparency and Accountability Act (H.R. 5463), which would amend the 340B statute to add a two-year moratorium on…
